February 16, 2016From Discovery to Development to Patient Delivery How TriCore Research Institute Pioneers Clinical Trial Support»
TriCore Reference Laboratories recent launch of the TriCore Research Institute (TRI) will support biotech companies that need validation for their ideas and technologies in early stages of research. It is…
January 19, 2016Developing Payer Strategies for Your New Technology»
Creating an effective payer strategy is necessary for success and Dr. Alan Wright, CMO of Roche Diagnostics, will share his experience in this area.
November 10, 2015BIO Review of BIO Economic Development Report and Advanced Translational Research Survey»
Join us for a webinar discussion led by Ray Zwahlen, Director of Technology Transfer and Associate Counsel, Biotechnology Industry Organization. Ray will review the Bioscience Economic Development Report and the Advanced Translational Research Study…
October 21, 2015NMBio October Meeting - NMSU Innovation Center Presentation»
Our presenter for this special meeting will be Theresa “Terry” Lombard, MBA, Director of Intellectual Property and Technology Transfer, Intellectual Property and Tech Transfer Office, Arrowhead Center, New Mexico State University. Our second presenter will be…
September 15, 2015Dealing with FDA Regulations and Other Issues in Developing Companion Diagnostic Programs»
Glen Freiberg will be presenting an innovative small company’s perspective on diagnostic product development. Epic Sciences’ “one-highway” program covers liquid biopsy assay development for academic and pharma investigational therapy and research partnerships, observational clinical trials and the evolution to CLIA/CAP, interventional studies, companion diagnostics and independent diagnostics.
August 11, 2015Diagnostic Testing for Targeted Cancer Therapeutics»
Personalized medicine attempts to tailor medical treatment to the individual’s characteristics and in oncology targets an individual’s tumor with a therapy tailored to the specific characteristics of a tumor. Successful development of targeted therapeutics often relies upon co-development with companion diagnostics. Identifying a specific, responsive patient population within a larger population can enable the approval of a therapeutic, but limit its intended use.
July 14, 2015ACI and the Impact of Policy on Business in New Mexico»
Eric Layer, Vice President of the New Mexico Association of Commerce and Industry, will review the recent New Mexico legislative session and the impact of policy upon economic development in New Mexico.
May 12, 2015Business Incentives and Programs in Albuquerque»
Get latest information on programs and incentives available through AED.